Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
McKinsey
Cantor Fitzgerald
Julphar
Colorcon
Cipla
AstraZeneca
Fuji
Baxter

Generated: April 19, 2018

DrugPatentWatch Database Preview

NASONEX Drug Profile

« Back to Dashboard

Which patents cover Nasonex, and when can generic versions of Nasonex launch?

Nasonex is a drug marketed by Merck Sharp Dohme and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty-three countries.

The generic ingredient in NASONEX is mometasone furoate. There are twenty-nine drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the mometasone furoate profile page.
Drug patent expirations by year for NASONEX
Pharmacology for NASONEX
Medical Subject Heading (MeSH) Categories for NASONEX
Synonyms for NASONEX
(11beta,16alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
(11beta,16alpha)-9,21-Dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methylpregna-1,4-diene-3,20-dione
(1R,2S,10S,11S,13R,14R,15S,17S)-1-CHLORO-14-(2-CHLOROACETYL)-17-HYDROXY-2,13,15-TRIMETHYL-5-OXOTETRACYCLO[8.7.0.0(2),?.0(1)(1),(1)?]HEPTADECA-3,6-DIEN-14-YL FURAN-2-CARBOXYLATE
(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
(9beta,10alpha,11alpha,14beta,16alpha,17alpha)-9,21-dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloranyl-17-(2-chloranylethanoyl)-10,13,16-trimethyl-11-oxidanyl-3-oxidanylidene-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
[(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloroacetyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] furan-2-carboxylate
04201GDN4R
11?,16?)-9,21-Dichloro-11-hydroxy-16-methyl-3,20-dioxopregna-1,4-dien-17-yl 2-furoate
2-furancarboxylic acid [(8S,9R,10S,11S,13S,14S,16R,17R)-9-chloro-17-(2-chloro-1-oxoethyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] ester
83919-23-7
9,21-dichloro-11beta-hydroxy-16alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl furan-2-carboxylate
9,21-Dichloro-11beta,17-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17-(2-furoate)
919M237
A840685
AB2000407
AC-941
AC1L9AZS
AK163902
AKOS015994732
AN-15438
Asmanex
Asmanex HFA
Asmanex Twisthaler
BC228151
BDBM50148733
BPBio1_000424
BRD-K60640630-001-03-7
BRN 4340538
BSPBio_000384
C07817
C27H30Cl2O6
CAS-83919-23-7
CCG-220572
CHEBI:47564
CHEMBL1161
CS-2389
D00690
Danitin
DR003147
DSSTox_CID_3333
DSSTox_GSID_23333
DSSTox_RID_76981
DTXSID4023333
Ecural
Elocon
Elocone
Elomet
Flumeta
HMS1569D06
HMS2096D06
HMS2235I14
HY-13693
KS-00000SPL
KS-1275
LAS 41002
M2354
MLS002153879
MolPort-003-849-257
Mometasone 17-(2-furoate)
mometasone 17-furoate
mometasone furancarboxylate
mometasone furoate
Mometasone furoate (JAN/USP)
Mometasone furoate [USAN:USP:JAN]
Mometasone furoate hydrate
Mometasone Furoate Impurity G
MOMETASONE FUROATE MONOHYDRATE
Mometasone furoate, >=98% (HPLC)
Mometasone furoate, European Pharmacopoeia (EP) Reference Standard
Mometasone Furoate, pharmaceutical secondary standard; traceable to USP, PhEur and BP
Mometasone furoate, United States Pharmacopeia (USP) Reference Standard
Monovo
NCGC00016950-01
NCGC00179578-01
NCGC00179578-03
NCGC00179578-04
Nosorex
NSC-746171
NSC746171
Ovixan
PL071566
Pregna-1,20-dione, 9,21-dichloro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-methyl-, (11.beta.,16.alpha.)-
Pregna-1,4-diene-3,20-dione, 9,21-dichloro-17-((2-furanylcarbonyl)oxy)-11-hydroxy-16-methyl-, (11beta,16alpha)-
Prestwick_924
Prestwick0_000572
Prestwick1_000572
Prestwick2_000572
Prestwick3_000572
Q-101380
Rimelon
s1987
Sch 32088
Sch-32088
SCHEMBL4568
Sinuva
SMR001233233
SPBio_002603
SR-01000841209
SR-01000841209-2
ST24048112
TL8005500
Tox21_110705
Tox21_110705_1
UNII-04201GDN4R
WOFMFGQZHJDGCX-ZULDAHANSA-N
ZINC3938677

US Patents and Regulatory Information for NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for NASONEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Merck Sharp Dohme NASONEX mometasone furoate SPRAY, METERED;NASAL 020762-001 Oct 1, 1997 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for NASONEX
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Nasal Spray 50 mcg/ Spray ➤ Subscribe 2009-08-07

Non-Orange Book US Patents for NASONEX

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,180,781 Process for making mometasone furoate monohydrate ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for NASONEX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0002 Belgium ➤ Try a Free Trial PRODUCT NAME: MOMETASONE FUROATE; NAT. REGISTRATION NO/DATE: NL 19601 19950919; FIRST REGISTRATION: GR - 10681/89 19900622
1998 Austria ➤ Try a Free Trial PRODUCT NAME: MOMETASON FUROAT MONOHYDRAT; NAT. REGISTRATION NO/DATE: 1-22208 19971111; FIRST REGISTRATION: FR AMM 343012.6 19970219
875032 Germany ➤ Try a Free Trial PRODUCT NAME: MOMETASON-FUROAT-MONOHYDRAT; NAT. REGISTRATION NO/DATE: 40803.00.00 19980218; FIRST REGISTRATION: FRANKREICH NL 22055 19970219
5/1998 Austria ➤ Try a Free Trial PRODUCT NAME: MOMETASON FUROAT MONOHYDRAT
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
Fuji
Covington
US Army
Queensland Health
Merck
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.